^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib

Published date:
10/15/2021
Excerpt:
HER2 exon 20 YVMA insertion tumors showed a potent and sustained response to the combination of mobocertinib and ado-trastuzumab emtansine (T-DM1).
DOI:
10.1158/0008-5472.CAN-21-1526